SZSE:300267

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥7.9b

Last Updated

2021/07/27 16:37 UTC

Data Sources

Company Financials

Executive Summary

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. More Details


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Hunan Er-Kang Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 300267 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 300267's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

-2.1%

300267

-7.2%

CN Pharmaceuticals

-2.0%

CN Market


1 Year Return

-20.3%

300267

-9.0%

CN Pharmaceuticals

9.4%

CN Market

Return vs Industry: 300267 underperformed the CN Pharmaceuticals industry which returned -9% over the past year.

Return vs Market: 300267 underperformed the CN Market which returned 9.4% over the past year.


Shareholder returns

300267IndustryMarket
7 Day-2.1%-7.2%-2.0%
30 Day0.5%-7.8%-2.4%
90 Day-1.8%-5.2%3.1%
1 Year-19.2%-20.3%-8.2%-9.0%10.8%9.4%
3 Year-5.0%-6.6%39.6%34.4%52.1%44.5%
5 Year-72.3%-73.0%41.2%33.4%31.9%22.7%

Long-Term Price Volatility Vs. Market

How volatile is Hunan Er-Kang Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hunan Er-Kang Pharmaceutical undervalued compared to its fair value and its price relative to the market?

28.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 300267 (CN¥3.82) is trading below our estimate of fair value (CN¥5.35)

Significantly Below Fair Value: 300267 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 300267 is poor value based on its PE Ratio (33.8x) compared to the CN Pharmaceuticals industry average (29.5x).

PE vs Market: 300267 is poor value based on its PE Ratio (33.8x) compared to the CN market (31.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 300267's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 300267 is good value based on its PB Ratio (1.3x) compared to the CN Pharmaceuticals industry average (2.7x).


Future Growth

How is Hunan Er-Kang Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hunan Er-Kang Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Hunan Er-Kang Pharmaceutical performed over the past 5 years?

-41.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 300267 has high quality earnings.

Growing Profit Margin: 300267's current net profit margins (10%) are higher than last year (3.9%).


Past Earnings Growth Analysis

Earnings Trend: 300267's earnings have declined by 41.2% per year over the past 5 years.

Accelerating Growth: 300267's earnings growth over the past year (146%) exceeds its 5-year average (-41.2% per year).

Earnings vs Industry: 300267 earnings growth over the past year (146%) exceeded the Pharmaceuticals industry 25%.


Return on Equity

High ROE: 300267's Return on Equity (3.9%) is considered low.


Financial Health

How is Hunan Er-Kang Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 300267's short term assets (CN¥2.9B) exceed its short term liabilities (CN¥890.4M).

Long Term Liabilities: 300267's short term assets (CN¥2.9B) exceed its long term liabilities (CN¥60.1M).


Debt to Equity History and Analysis

Debt Level: 300267's debt to equity ratio (11.3%) is considered satisfactory.

Reducing Debt: 300267's debt to equity ratio has increased from 4.3% to 11.3% over the past 5 years.

Debt Coverage: 300267's debt is well covered by operating cash flow (60.7%).

Interest Coverage: 300267 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Hunan Er-Kang Pharmaceutical current dividend yield, its reliability and sustainability?

1.31%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 300267's dividend (1.31%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).

High Dividend: 300267's dividend (1.31%) is low compared to the top 25% of dividend payers in the CN market (1.87%).


Stability and Growth of Payments

Stable Dividend: 300267 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 300267's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (44.2%), 300267's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.7yrs

Average management tenure


CEO

Fangwen Shuai (54 yo)

no data

Tenure

CN¥440,000

Compensation

Mr. Fangwen Shuai serves as the Chairman, Chief executive Officer and Secretary of Hunan Er-Kang Pharmaceutical Co., Ltd.


Leadership Team

Experienced Management: 300267's management team is seasoned and experienced (8.7 years average tenure).


Board Members

Experienced Board: 300267's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hunan Er-Kang Pharmaceutical Co., Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hunan Er-Kang Pharmaceutical Co., Ltd
  • Ticker: 300267
  • Exchange: SZSE
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥7.879b
  • Shares outstanding: 2.06b
  • Website: https://www.hnerkang.com

Number of Employees


Location

  • Hunan Er-Kang Pharmaceutical Co., Ltd
  • Liuyang National Economic & Technical Development Zone
  • Liuyang
  • Hunan Province
  • China

Listings


Biography

Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, d...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/27 16:37
End of Day Share Price2021/07/27 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.